ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)
Tests whether giving a TROP2 ADC after surgery can cure more of the triple-negative patients whose cancer survived pre-surgery chemo-immunotherapy.
International randomised phase 3 in the highest-risk curable TNBC population: residual disease (non-pCR) after KEYNOTE-522-type neoadjuvant therapy. Primary endpoint invasive disease-free survival. If positive, it would be the first ADC in the curative TNBC setting and the KATHERINE moment for TNBC. Readout is event-driven; our estimate is 2027.
Pages like this
not linked directly; found by shared links- Key paperKEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer
Shares Residual cancer burden (RCB), ADC for residual disease after KEYNOTE-522, KEYNOTE-522, Event-free / disease-free survival (EFS, DFS, iDFS, RFS).
- IdeaNeoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC
Shares KEYNOTE-522, Sacituzumab govitecan, Pembrolizumab, Triple-negative breast cancer (TNBC).
- PersonLaura J. Esserman
Shares Residual cancer burden (RCB), Pathologic complete response (pCR), Triple-negative breast cancer (TNBC).
- TrialOptimICE-pCR (A012103)
Shares Pathologic complete response (pCR), Pembrolizumab, Triple-negative breast cancer (TNBC).
- IdeaPre-surgery platform trials that test combinations on pathological response in months
Shares Residual cancer burden (RCB), KEYNOTE-522, Pathologic complete response (pCR).
- TrialKEYNOTE-716
Shares Event-free / disease-free survival (EFS, DFS, iDFS, RFS), Pembrolizumab.
- TrialASCENT-04 / KEYNOTE-D19
Shares Sacituzumab govitecan, Pembrolizumab, Triple-negative breast cancer (TNBC).
- Key paperKATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment
Shares Residual cancer burden (RCB), ADC for residual disease after KEYNOTE-522, Pathologic complete response (pCR).